N2OFF shares surge 23.08% after-hours after MitoCareX Bio reports positive in vitro results from mitochondrial carrier platform.

N2OFF, Inc. (NITO) surged 23.08% in after-hours trading following the announcement of MitoCareX Bio’s innovative research on mitochondrial carriers in microgravity and cosmic radiation conditions, reported by GlobeNewswire four days ago. This development highlights the company’s progress in addressing mitochondrial dysfunction under extreme spaceflight stress, a key focus for biotech advancements. Additionally, positive in vitro results from MitoCareX’s mitochondrial carrier platform, disclosed 15 days prior, reinforced investor confidence in its drug discovery pipeline targeting resistant cancers. These recent scientific milestones, coupled with ongoing European renewable energy project advancements, positioned N2OFF as a high-growth biotech and clean energy play, driving significant post-market gains.